Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX opened at $0.65 on Wednesday. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $9.10. The stock has a fifty day moving average price of $1.87 and a 200 day moving average price of $3.67.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in Eagle Pharmaceuticals in the second quarter worth approximately $971,000. Vanguard Group Inc. lifted its position in shares of Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after buying an additional 2,630 shares during the last quarter. Creative Planning bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $59,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Eagle Pharmaceuticals during the 1st quarter valued at about $83,000. Finally, Fidelis Capital Partners LLC bought a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.